ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/KRAS
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/KRAS
32
trial(s) found.
NCT07535112
Advanced
Phase 1
Recruiting
Master Protocol: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BAY 3771249 as Monotherapy or Combination With Other Cancer Treatments in Participants With Solid Tumors Harboring a KRAS G12D Mutation. Substudy Protocol: An Open-label, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of BAY 3771249 as Monotherapy and in Combination With Cetuximab in Participants With Advanced/Metastatic Colorectal Adenocarcinoma Harboring a KRAS G12D Mutation (
23111-1
)
KRAS G12D inhibitor
Colorectal adenocarcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT07522073
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (
DAWN-303
)
KRAS G12D inhibitor
Pancreatic adenocarcinoma
NSW
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Cancer Care Wollongong
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3121 - Richmond - Epworth Freemasons Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07415031
Advanced
Phase 2
Recruiting
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503) (
CA239-0071
)
KRAS G12C inhibitor
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
NCT07247110
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors (
4716-001
)
pan-KRAS inhibitor
Cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT07209111
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (
KANDLELIT-014
)
KRAS G12C inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07204340
Advanced
Phase 1
Recruiting
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors (
TLN-372-2501
)
pan-KRAS inhibitor
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07190248
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007) (
1084-007
)
KRAS G12C inhibitor
antimetabolite
platinum-based antineoplastic agent
Non-small cell lung cancer
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2560 - Campbelltown - GenesisCare Campbelltown
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07172919
Advanced
Phase 2
Recruiting
A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study
anti-EGFR monoclonal antibody
+ KRAS G12C/NRAS G12C/HRAS G12C inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
NCT07094113
Advanced
Phase 1
Recruiting
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
pan-KRAS inhibitor
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07020221
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors (
VS-7375-101
)
KRAS G12D inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT06997497
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012) (
1084-012
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
+ KRAS G12C inhibitor
Colon adenocarcinoma
Rectal adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06890598
Curative
Phase 3
Recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer -
SUNRAY-02
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06884618
Advanced
Phase 1
Recruiting
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) (
YO45758
)
pan-KRAS inhibitor
Cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06881784
Advanced
Phase 3
Recruiting
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (
RASolve-301
)
pan-KRAS inhibitor
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06875310
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) (
CA239-0004
)
KRAS G12C inhibitor
placebo
Non-small cell lung cancer
NSW
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3066 - Epping - Northern Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6027 - Joondalup - Joondalup Health Campus
NCT06804824
Advanced
Phase 1
Recruiting
A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors (
VVD-159642-01
)
RAS-PI3Kalpha inhibitor
+ KRAS G12C/NRAS G12C/HRAS G12C inhibitor
NOT Central nervous system cancer
Solid tumour
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06793215
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (
Krascendo-2
)
KRAS G12C inhibitor
antimetabolite
platinum-based antineoplastic agent
Lung cancer
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT06764771
Advanced
Phase 1
Recruiting
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors (
CA234-0001
)
KRAS G12C inhibitor
Cancer
QLD
4032 - Chermside - The Prince Charles Hospital
NCT06659341
Advanced
Phase 1
Recruiting
Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors
SOS1-KRAS inhibitor
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT06619587
Advanced
Phase 1
cohorts full
A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation (
GO45416
)
KRAS G12D inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06345729
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004) (
1084-004
)
KRAS G12C inhibitor
placebo
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06343402
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study (
TBBO8520-101
)
KRAS G12C inhibitor
Colorectal adenocarcinoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06252649
Advanced
Phase 3
Recruiting
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) (
CodeBreaK-301
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4350 - Toowoomba - Toowoomba Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT06244771
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (
PROSPER
)
KRAS G12C inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Tasman Oncology
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NCT06179160
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (
INCB161734-101
)
KRAS G12D inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NCT06162221
Advanced
Phase 1 / Phase 2
Recruiting
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) (
RMC-LUNG-101
)
Carboplatin
Cisplatin
Daraxonrasib
Elironrasib
KRAS G12C inhibitor
KRAS inhibitor
Pembrolizumab
Pemetrexed
anti-PD-1 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,KRAS-targeting
cancer therapy,KRAS G12C-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
pan-KRAS inhibitor
platinum-based antineoplastic agent
+ KRAS G12C inhibitor
Cancer
Lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06119581
Advanced
Phase 3
Recruiting
SUNRAY-01
, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
KRAS G12C inhibitor
antimetabolite
Non-small cell lung cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05789082
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (
KRAScendo-170
)
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT05410145
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (
D3S-001-100
)
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05067283
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (
KANDLELIT-001
)
KRAS G12C inhibitor
Colorectal cancer
NOT Non-small cell lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04929223
Advanced
Phase 1
Recruiting
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (
WO42758
)
Atezolizumab
Bevacizumab
CDK7 inhibitor
Cetuximab
Divarasib
Inavolisib
KRAS G12C inhibitor
KRAS inhibitor
PI3K alpha inhibitor
SY-5609
Tiragolumab
anti-EGFR monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,CDK7-targeting
cancer therapy,EGFR-targeting
cancer therapy,KRAS-targeting
cancer therapy,KRAS G12C-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,EGFR-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ KRAS G12C inhibitor
Colorectal adenocarcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04613596
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (
CA239-0009
)
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Cancer Care Wollongong
ACT
2605 - Garran - The Canberra Hospital
VIC
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (31)
cohorts full (1)
Recruitment Country and State
NSW (27)
VIC (27)
WA (14)
QLD (12)
SA (11)
NZ (6)
ACT (3)
TAS (1)
Phase
Phase 1 (13)
Phase 1 / Phase 2 (5)
Phase 2 (3)
Phase 2 / Phase 3 (1)
Phase 3 (10)
Trial Type
Advanced (31)
Curative (1)
Cancer Therapy Class
KRAS
100%
KRAS G12C
69%
PD-1/PD-L1
63%
PD-1
59%
EGFR
47%
KRAS G12D
16%
HRAS G12C
13%
NRAS G12C
13%
VEGF
9%
PI3Kalpha
9%
PD-L1
6%
ERBB2
3%
HRAS
3%
MEK
3%
NRAS
3%
DPD
3%
orotate phosphoribosyltransferase
3%
TGFBR2
3%
CDK7
3%
TIGIT
3%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (9)
2050 - Camperdown - Chris O'Brien Lifehouse (7)
3168 - Clayton - Monash Medical Centre (6)
6009 - Nedlands - Linear Clinical Research (6)
3004 - Melbourne, Southbank - Alfred Health (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
3199 - Frankston - Peninsula Health Frankston Hospital (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
2170 - Liverpool - Liverpool Hospital (4)
4575 - Birtinya - Sunshine Coast University Hospital (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
5042 - Bedford Park - Flinders Medical Centre (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
2605 - Garran - The Canberra Hospital (3)
5011 - Woodville South - The Queen Elizabeth Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2109 - North Ryde - Macquarie University Hospital (3)
2640 - Albury - Albury Wodonga Regional Cancer Centre (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2500 - Wollongong - Cancer Care Wollongong (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
6009 - Nedlands - One Clinical Research (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
4032 - Chermside - The Prince Charles Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (2)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (2)
3630 - Shepparton - Goulburn Valley Health (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
3121 - Richmond - Epworth Freemasons Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2500 - Wollongong - Wollongong Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3066 - Epping - Northern Hospital (1)
6027 - Joondalup - Joondalup Health Campus (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4215 - Southport - Tasman Oncology (1)
NA
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
4215 - Southport - Gold Coast University Hospital (1)
4740 - Mackay - Mackay Base Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Colorectal adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Colon adenocarcinoma
Rectal adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy